CRNX (Crinetics Pharmaceuticals, Inc.) Stock Analysis - Analyst Ratings

Crinetics Pharmaceuticals, Inc. (CRNX) is a publicly traded Healthcare sector company. As of May 21, 2026, CRNX trades at $36.28 with a market cap of $3.66B and a P/E ratio of -7.30. CRNX moved +3.84% today. Year to date, CRNX is -24.72%; over the trailing twelve months it is +15.62%. Its 52-week range spans $24.10 to $62.53. Analyst consensus is strong buy with an average price target of $86.00. Rallies surfaces CRNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate CRNX?

10 analysts cover CRNX: 0 strong buy, 10 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $86.00.

CRNX Key Metrics

Key financial metrics for CRNX
MetricValue
Price$36.28
Market Cap$3.66B
P/E Ratio-7.30
EPS$-4.95
Dividend Yield0.00%
52-Week High$62.53
52-Week Low$24.10
Volume581.00K
Avg Volume0
Revenue (TTM)$7.70M
Net Income$-465.32M
Gross Margin86.02%

CRNX Analyst Consensus

10 analysts cover CRNX: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $86.00.

Latest CRNX News

Recent CRNX Insider Trades

  • Knight Jeff E. sold 85.16K (~$3.42M) on Apr 8, 2026.
  • Knight Jeff E. sold 5.95K (~$220.80K) on Mar 16, 2026.
  • Knight Jeff E. sold 3.96K (~$149.61K) on Mar 16, 2026.

Common questions about CRNX

What do analysts rate CRNX?
10 analysts cover CRNX: 0 strong buy, 10 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $86.00.
Does Rallies show CRNX price targets?
Yes. Rallies tracks CRNX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is CRNX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CRNX. It does not provide personalized investment advice.
CRNX

CRNX